Get the Stockscreener App
0.6374
10.16%
0.0624
Lexicon Pharmaceuticals Inc stock is traded at $0.6374, with a volume of 11.34M.
It is up +10.16% in the last 24 hours and up +74.39% over the past month.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.
See More
Previous Close:
$0.575
Open:
$0.5788
24h Volume:
11.34M
Relative Volume:
0.80
Market Cap:
$221.49M
Revenue:
$1.21M
Net Income/Loss:
$-177.12M
P/E Ratio:
-0.7968
EPS:
-0.8
Net Cash Flow:
$-162.37M
1W Performance:
+23.69%
1M Performance:
+74.39%
6M Performance:
-67.35%
1Y Performance:
-62.96%
1-Day Range:
$0.577
$0.6445
1-Week Range:
$0.48
$0.6445
52-Week Range:
$0.2836
$2.45
Lexicon Pharmaceuticals Inc Stock (LXRX) Company Profile
Name
Lexicon Pharmaceuticals Inc
Sector
Industry
Phone
(281) 863-3000
Address
2445 TECHNOLOGY FOREST BLVD., THE WOODLANDS
Compare LXRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LXRX
Lexicon Pharmaceuticals Inc
|
0.6374 | 221.49M | 1.21M | -177.12M | -162.37M | -0.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.69 | 128.67B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
583.23 | 60.99B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
600.69 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
236.00 | 29.89B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.09 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Lexicon Pharmaceuticals Inc Stock (LXRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-05-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-17-24 | Initiated | H.C. Wainwright | Buy |
| Apr-30-24 | Initiated | Leerink Partners | Outperform |
| Mar-07-23 | Initiated | Jefferies | Hold |
| Aug-12-22 | Initiated | Piper Sandler | Overweight |
| Jan-29-21 | Upgrade | JP Morgan | Underweight → Neutral |
| Jan-29-21 | Downgrade | Wedbush | Outperform → Neutral |
| Dec-08-20 | Upgrade | Citigroup | Neutral → Buy |
| Nov-18-20 | Upgrade | Gabelli & Co | Hold → Buy |
| Dec-11-19 | Downgrade | Gabelli & Co | Buy → Hold |
| Nov-08-19 | Downgrade | Citigroup | Buy → Neutral |
| Sep-11-19 | Upgrade | Gabelli & Co | Hold → Buy |
| Jul-29-19 | Downgrade | Stifel | Buy → Hold |
| Mar-25-19 | Upgrade | Gabelli & Co | Sell → Hold |
| Jul-31-18 | Reiterated | Stifel | Buy |
| Feb-23-18 | Downgrade | Needham | Buy → Hold |
| Feb-14-18 | Downgrade | JP Morgan | Neutral → Underweight |
| Mar-01-17 | Reiterated | H.C. Wainwright | Buy |
| Mar-01-17 | Reiterated | Wedbush | Outperform |
| Oct-07-16 | Initiated | H.C. Wainwright | Buy |
| Aug-05-16 | Reiterated | Wedbush | Outperform |
| Aug-02-16 | Initiated | Citigroup | Buy |
| Mar-02-16 | Reiterated | Wedbush | Outperform |
| Nov-09-15 | Reiterated | Wedbush | Outperform |
| Sep-28-15 | Upgrade | Gabelli & Co | Sell → Hold |
| Sep-18-15 | Downgrade | Gabelli & Co | Hold → Sell |
| Aug-10-15 | Downgrade | JP Morgan | Overweight → Neutral |
View All
Lexicon Pharmaceuticals Inc Stock (LXRX) Latest News
Form ARS LEXICON PHARMACEUTICALS, For: Dec 31 - StreetInsider
Lexicon Pharmaceuticals at Needham Conference: Strategic Shift in Focus By Investing.com - Investing.com Canada
Novo Nordisk inks licensing pact with Lexicon for obesity candidate - MSN
LXRX Stock Moves Up 30% in a Week: What is Driving This Rally? - MSN
Lexicon Pharmaceuticals to present at Healthcare Conference By Investing.com - Investing.com South Africa
Lexicon Pharmaceuticals to present at Healthcare Conference - Investing.com
Lexicon Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference - The Manila Times
Lexicon Pharma (LXRX) to Present at the 24th Annual Needham Virtual Healthcare Conference - StreetInsider
Social Buzz: Wallstreetbets Stocks Mixed Premarket Tuesday; Tesla to Advance, Lexicon Pharmaceuticals to Decline - MarketScreener
Lexicon Pharmaceuticals Sees Unusually High Options Volume (NASDAQ:LXRX) - MarketBeat
Novo Nordisk gains rights to novel small molecule inhibitor - European Pharmaceutical Review
Houston-area company inks massive $1B deal for weight-loss drug - Chron
Novo Nordisk licenses Lexicon’s preclinical obesity drug in $1B deal - BioWorld MedTech
US Stocks Likely To Open Lower After 3-Day Fall: 'Equity Drawdown Probability Hasn't Peaked Yet,' Says Goldman Sachs Analyst - Benzinga
The Woodlands-based company strikes obesity-drug license deal worth up to $1B - KHOU
Biotech Firms Celebrate Gains With Promising Trials And Partnerships - Finimize
Lexicon's Drug Discovery Engine Validated By Novo's $1 Billion Obesity Drug Deal (Upgrade) - Seeking Alpha
Novo Nordisk Inks Its Second Big Obesity Deal In A Week — And It's Not For A GLP-1 - Investor's Business Daily
What 6 Analyst Ratings Have To Say About Lexicon Pharmaceuticals - Fidelity
Novo Nordisk Lands Lexicon Pharma Obesity Drug With Potential to Pair With GLP-1s - MedCity News
Lexicon Pharmaceuticals, Novo Nordisk strike obesity-drug license deal worth up to $1B - The Business Journals
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Novo Nordisk strikes $1bn deal for Lexicon’s oral obesity drug - Yahoo Finance
Lexicon (LXRX) Secures $1 Billion Deal with Novo Nordisk for Obe - GuruFocus
Novo Adds Lexicon’s Novel Obesity Drug To Deal Flurry - insights.citeline.com
Novo Nordisk to license obesity drug from Lexicon in up to $1 billion deal - Reuters
Lexicon Pharmaceuticals: Strategic Partnerships and Pipeline Advancements Drive Buy Rating - TipRanks
Lexicon Pharma soars as it licenses LX9851 to Novo Nordisk - The Pharma Letter
Nasdaq Down 100 Points; Federal Reserve's Favorite Inflation Gauge Increases More Than Expected - Benzinga
Lexicon inks $1 billion deal with Novo Nordisk for obesity drug By Investing.com - Investing.com South Africa
Lexicon stock rises on Novo Nordisk licensing deal (LXRX) - Seeking Alpha
Sector Update: Health Care Stocks Steady Premarket Friday - MarketScreener
Lexicon Pharmaceuticals (LXRX) Soars 95% on Novo Nordisk Licensi - GuruFocus.com
Penny Stock Lexicon Pharmaceuticals Surges On Obesity Pact Worth $1 Billion With Novo Nordisk - Benzinga
Novo Nordisk in licensing deal with Lexiconcould pay up to $1 billion - MarketScreener
Lexicon inks $1 billion deal with Novo Nordisk for obesity drug - Investing.com India
Lexicon Pharmaceuticals Enters License Agreement With Novo Nordisk for Obesity Drug; Shares Jump - MarketScreener
Lexicon Pharmaceuticals Announces Exclusive License Agreement With Novo Nordisk For LX9851 - Marketscreener.com
Lexicon Pharma (LXRX) Announces Exclusive License Agreement with Novo Nordisk for LX9851 - StreetInsider
Lexicon's Game-Changing Obesity Drug Catches Novo Nordisk's Eye in Billion-Dollar Deal - Stock Titan
Chronic Neuropathic Pain Market to Reach New Heights in Growth - openPR
Lexicon Pharmaceuticals Inc Stock (LXRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Lexicon Pharmaceuticals Inc Stock (LXRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Swain Judith L | Director |
Apr 28 '24 |
Option Exercise |
0.00 |
8,032 |
0 |
48,364 |
| SOBECKI CHRISTOPHER J | Director |
Apr 28 '24 |
Option Exercise |
0.00 |
8,032 |
0 |
167,055 |
| LEFKOWITZ ROBERT J MD | Director |
Apr 28 '24 |
Option Exercise |
0.00 |
8,032 |
0 |
48,364 |
| DEBBANE RAYMOND | Director |
Apr 28 '24 |
Option Exercise |
0.00 |
8,032 |
0 |
1,348,879 |
| BARKER SAM L | Director |
Apr 28 '24 |
Option Exercise |
0.00 |
8,032 |
0 |
87,649 |
| Amouyal Philippe | Director |
Apr 28 '24 |
Option Exercise |
0.00 |
8,032 |
0 |
248,364 |
1.75%
2.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):